Association of DNA repair gene polymorphisms with response to cisplatin-based concurrent chemoradiotherapy in patients with cervical carcinoma

DNA Repair (Amst). 2016 May:41:69-72. doi: 10.1016/j.dnarep.2016.03.015. Epub 2016 Apr 6.

Abstract

Purpose: The aim of this study was to investigate polymorphisms in DNA repair genes as potential predictive factors among Chinese cervical cancer patients.

Methods: A total of 72 patients with cervical carcinoma, who received cisplatin-based chemoradiotherapy and whose responses were evaluated by Response Evaluation Criteria in Solid Tumors, were included. The association between response to chemoradiotherapy and the genotypes for 29 single-nucleotide polymorphisms (SNPs) in 25 DNA repair genes were analyzed.

Results: A minor allele of SNP rs9350 in the exonuclease 1 gene was associated with a better response rate, regardless of age and tumor stage (odds ratio, 8.316; p=0.002).

Conclusion: SNP rs9350 in the exonuclease 1 gene is involved in inter-individual differences in the response to cisplatin-based chemoradiotherapy, in patients with cervical carcinoma.

Keywords: Cervical carcinoma; Chemoradiotherapy; Exonuclease 1; Polymorphisms; Response.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chemoradiotherapy*
  • Cisplatin / pharmacology*
  • Cisplatin / therapeutic use
  • Female
  • Humans
  • Middle Aged
  • Polymorphism, Single Nucleotide*
  • Treatment Outcome
  • Tumor Burden / drug effects
  • Uterine Cervical Neoplasms / drug therapy*
  • Uterine Cervical Neoplasms / genetics*
  • Uterine Cervical Neoplasms / pathology
  • Uterine Cervical Neoplasms / therapy

Substances

  • Cisplatin